CSI Market
Sign In | Register

Cg Oncology Inc (CGON) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CGON Annual Cash Flow →
Examining cash flow movements between Cg Oncology Inc and Jun 30 2025 reveals how Jun 30 2026 allocates cash as operating conditions evolve.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
6 Months 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Operating Activities
Income-139.26
Depreciation & amortization1.69
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-0.56
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation20.81
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Amortization Of Loan Fees-
Final Payment Amortization-
Success Fees Amortization-
Investment Income Net Amortization Of Discount And Premium-
Non Cash Lease Expense0.01
Income taxes0.00
Unrealized Gain (Loss) on Investments-4.67
Increase (Decrease) in Accounts Receivable-0.27
Increase (Decrease) in Accounts Payable7.01
Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities9.35
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets4.88
Other Working Capital2.40
Other Noncash Income (Expense)-0.09
Other net0.00
Payments for (Proceeds from) Other Operating Activities-4.64
Discontinued operations0.00
Net Cash flow from Operating Activities-103.36
Investing Activities
Capital Expenditures-0.77
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments-303.65
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Payments to Acquire Notes Receivable0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-304.42
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock395.11
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net-0.19
Other net0.00
Payments Of Success Fee Or Long Term Debt-
Deferred Offering Cost-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents32.49
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities394.92
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-104.13
Total Cash Flow-12.85
4 historic quarters locked

Sign in to unlock the full Cg Oncology Inc cash flow history.

Sign In Create Free Account

About Cg Oncology Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-336918

Figures are derived from filed reports and may be restated. Historical data is subject to revision.